Published in Blood on May 27, 2010
Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am (2013) 1.10
Heparin modifies the immunogenicity of positively charged proteins. Blood (2010) 1.00
Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program (2013) 0.91
Novel diagnostic assays for heparin-induced thrombocytopenia. Blood (2013) 0.89
Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. Ther Adv Hematol (2012) 0.87
Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia. Am J Hematol (2012) 0.83
The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up. PLoS One (2013) 0.81
Improving specificity in HIT testing. Blood (2010) 0.76
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. Blood (2011) 0.76
The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery. J Thromb Haemost (2016) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Evaluating the yield of medical tests. JAMA (1982) 14.05
Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2006) 3.11
Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.07
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost (2004) 2.04
A 14-year study of heparin-induced thrombocytopenia. Am J Med (1996) 2.03
The performance of risk prediction models. Biom J (2008) 2.00
Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost (2004) 1.79
Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost (2008) 1.75
Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost (2008) 1.61
Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost (2005) 1.40
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med (2005) 1.38
Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost (2007) 1.31
Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol (2005) 1.10
Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J (2007) 0.94
Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med (2002) 0.93
Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost (2007) 0.92
No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost (2006) 0.88
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol (2009) 3.54
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2006) 3.11
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med (2012) 3.04
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
RNA aptamers as reversible antagonists of coagulation factor IXa. Nature (2002) 2.73
Venous thromboembolism: a public health concern. Am J Prev Med (2010) 2.37
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Ann Intern Med (2013) 2.15
Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. Am J Med (2005) 2.08
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med (2014) 1.67
Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost (2008) 1.61
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol (2013) 1.61
Dynamic antibody-binding properties in the pathogenesis of HIT. Blood (2012) 1.59
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood (2005) 1.59
Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol (2009) 1.55
Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. Am J Hematol (2007) 1.54
Coronary artery pattern and outcome of arterial switch operation for transposition of the great arteries: a meta-analysis. Circulation (2002) 1.50
Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg (2009) 1.49
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood (2012) 1.48
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med (2013) 1.39
Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med (2003) 1.38
Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. Circulation (2009) 1.36
Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit (2010) 1.36
Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. J Am Coll Cardiol (2013) 1.34
Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol (2005) 1.31
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease. Psychosom Med (2013) 1.24
Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. Am J Cardiol (2005) 1.20
High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood (2013) 1.16
Retracted Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood (2005) 1.12
Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am (2013) 1.10
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.06
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood (2004) 1.06
Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol (2009) 1.05
Coagulation and inflammation in acute lung injury. Thromb Haemost (2002) 1.03
Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg (2003) 1.02
Venous thromboembolic disease. J Natl Compr Canc Netw (2013) 1.01
Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg (2005) 1.01
Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. J Thromb Thrombolysis (2012) 1.00
Heparin modifies the immunogenicity of positively charged proteins. Blood (2010) 1.00
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl (2009) 1.00
The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth (2006) 0.98
Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.98
Associations of depressive symptoms, trait hostility, and gender with C-reactive protein and interleukin-6 response after emotion recall. Psychosom Med (2010) 0.98
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol (2007) 0.97
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J (2004) 0.97
Coagulation abnormalities in patients with hip osteonecrosis. Orthop Clin North Am (2004) 0.95
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes (2011) 0.95
Heparin-induced thrombocytopenia. Annu Rev Med (2010) 0.95
Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med (2006) 0.93
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program (2013) 0.91
Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol (2002) 0.91
Acquired, non-amyloid related factor X deficiency: review of the literature. Haemophilia (2012) 0.91
Thrombophilias: when should we test and how does it help? Semin Respir Crit Care Med (2008) 0.90
Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol (2004) 0.89
Novel diagnostic assays for heparin-induced thrombocytopenia. Blood (2013) 0.89
Portfolio of clinical research in adult cardiovascular disease as reflected in ClinicalTrials.gov. J Am Heart Assoc (2013) 0.88
Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. Thromb Haemost (2012) 0.88
Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thromb Res (2011) 0.88
Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol (2005) 0.87
Antithrombotic therapy and invasive procedures. N Engl J Med (2013) 0.87
Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes. Am J Med (2005) 0.87
Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2008) 0.87
Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. J Thromb Thrombolysis (2007) 0.87
Warfarin in antiphospholipid syndrome--time to explore new horizons. J Rheumatol (2005) 0.86
A new anatomic score for prognosis after cardiac catheterization in patients with previous bypass surgery. J Am Coll Cardiol (2005) 0.85
Long-term clinical outcomes following coronary stenting. Arch Intern Med (2008) 0.85
Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group. Am J Med (2011) 0.85
Characterization of the hypercoagulable state in patients with sickle cell disease. Thromb Res (2012) 0.85
Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding. Thromb Haemost (2003) 0.84
Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial (2003) 0.84
Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med (2002) 0.83
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement? Europace (2011) 0.83
Platelet factor 4-heparin complexes trigger immune responses independently of the MyD88 pathway. Br J Haematol (2008) 0.82
Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia. Am J Obstet Gynecol (2004) 0.82
2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol (2017) 0.82
A review of the therapeutic uses of thrombin. Thromb Haemost (2004) 0.81
Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg (2005) 0.81
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? Annu Rev Med (2015) 0.81
Influence of sample collection and storage on the detection of platelet factor 4-heparin antibodies. Am J Clin Pathol (2007) 0.80
ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT? Hematology Am Soc Hematol Educ Program (2009) 0.80